Related Experiment Video
Updated: Aug 4, 2026
08:01
Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
Immunological dysfunction in Alzheimer's disease
Journal of Neuroimmunology
|February 1, 1985
Summary
Alzheimer's patients exhibit significantly reduced interleukin-1 (IL-1) production and autologous rosette-forming cells (ARFC), alongside elevated B-cell glucose metabolism. These findings suggest potential biomarkers for Alzheimer's disease progression and therapeutic targets.
Area of Science:
- Immunology
- Neuroscience
- Gerontology
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
- Immune system dysregulation is implicated in AD pathogenesis.
- Interleukin-1 (IL-1) is a key inflammatory cytokine with a potential role in AD.
Purpose of the Study:
- To investigate interleukin-1 (IL-1) production in peripheral blood lymphocytes of Alzheimer's patients.
- To explore correlations between IL-1 levels, clinical symptoms, and specific therapies in AD.
- To assess other immune cell parameters, such as autologous rosette-forming cells (ARFC) and B-cell glucose metabolism, in AD patients.
Main Methods:
- Peripheral blood lymphocytes were isolated from Alzheimer's patients and healthy elderly controls.
- Interleukin-1 (IL-1) production by monocytes was measured in vitro.
- The number of autologous rosette-forming cells (ARFC) was quantified.
- B-cell glucose metabolism was assessed.
Main Results:
- Alzheimer's patients demonstrated severely low production of IL-1 by peripheral blood monocytes.
- Low IL-1 production correlated with clinical symptoms and 1-acetamide,2-pyrrolidone (1a,2p) therapy.
- A significant decrease in autologous rosette-forming cells (ARFC) was observed in all AD patients.
- B-cell glucose metabolism was significantly higher in AD patients compared to age-matched healthy individuals.
Conclusions:
- Reduced IL-1 production and ARFC counts may serve as potential indicators in Alzheimer's disease.
- Elevated B-cell glucose metabolism presents a novel finding in AD.
- These immune alterations warrant further investigation for diagnostic and therapeutic implications in Alzheimer's disease.
More Related Videos
10:19Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
09:33Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:23Role of Neurotransmitters in Memory
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is critical for...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is critical for...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...